Novo Nordisk invests DKK5.4 bn Danish kroner in expansion of clinical manufacturing installations in Bagsværd, Denmark
Novo Nordisk moment blazoned plans to invest5.4 bn Danish kroner in the expansion of being installations in Bagsværd. The plans also include the construction of a new factory located in extension of the being installations.
The investment will establish fresh capacity in R&D for manufacturing of active pharmaceutical constituents( API) to supply our global clinical trials. These expansions will give capacity for developing Novo Nordisk’s future oral and injectable product portfolio.
“ This investment in expanding our clinical API capacity in Bagsværd is an important step to insure the nonstop progress of our development channel. adding our API capacity in R&D will be a crucial enabler in bringing new inventions to the request, and meet the unborn demand of our cases ”, said Jesper Bøving, elderly vice chairman, CMC Development, Novo Nordisk.
The investment design is anticipated to be finalised in 2024 and will produce around 160 new jobs.
Novo Nordisk is a leading global healthcare company, innovated in 1923 and headquartered in Denmark. Our purpose is to drive change to master diabetes and other serious habitual conditions similar as rotundity and rare blood and endocrine diseases. We do so by introducing scientific improvements, expanding access to our drugs, and working to help and eventually cure complaint. Novo Nordisk employs about,000 people in 80 countries and requests its products in around 170 countries. For further information, visitnovonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Source link: https://www.novonordisk.com/
